Pasar al contenido principal

ALTERACIONES MOLECULARES EN EL MODELO MURINO FXNI151F DE ATAXIA DE FRIEDREICH Y ANALISIS DE NUEVAS ESTRATEGIAS TERAPEUTICAS

PID2023-148128OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE LLEIDA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Pathological frataxin deficiency in mice causes tissue-specific alterations in iron homeostasis

  • Pazos Gil, Maria
  • Medina Carbonero, Marta
  • Sanz Alcázar, Arabela
  • Portillo-Carrasquer, Marta
  • Oliveira-Jorge, Luiza
  • Hernández, Gonzalo
  • Sánchez, Mayka
  • Delaspre, Fabien
  • Cabiscol Català, Elisa
  • Ros Salvador, Joaquim
  • Tamarit Sumalla, Jordi
Friedreich ataxia is caused by partial frataxin deficiency due to genetic mutations. It is well established that frataxin knockout affects iron homeostasis, but the alterations caused by pathological (partial) frataxin deficiency are poorly understood. In this study, we have analyzed iron homeostasis in a mouse model presenting pathological frataxin deficiency (FXNI151F). Our results reveal tissue-specific alterations of iron regulatory proteins (IRPs). In the heart, IRP2 accumulation is observed, likely triggered by iron-sulfur deficiency, while IRP1 is decreased in the cerebellum and liver. We also found elevated iron levels in mutant mice. Accumulation was particularly pronounced in the cerebellum, where increases were already evident at 10 weeks. Hepatic accumulation was not manifested until 21 weeks and was more pronounced in females. Overall, these findings indicate that frataxin deficiency disrupts iron homeostasis in a tissue-, age-, and sex-dependent manner, and provide novel insights into the mechanisms causing these perturbations., We thank Roser Pané for technical assistance, as well as the Proteomics and the Elemental Analysis Services from Universitat de Lleida, the Animal facilities from Universitat de Lleida, and the Lipidomics services from IRBLleida. We also thank Dr. Bruno Galy (Heidelberg) for providing samples from IRP2 KO mice. This study was supported by grant PID2020-118296RB-I00 from MCIN/AEI/10.13039/501100011033 (to J.R. and J.T.); grant PID2023-148128OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by FEDER, UE (to J.T. and E.C.); and grant PID2021-122436OB-I00 from MCIN/AEI/10.13039/501100011033/ERDF “A way to make Europe” (to M.S.), and by Association Française de l'Ataxie de Friedreich – AFAF (to F.D.).
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Targeting frataxin deficiency in DRG neurons and fibroblasts: omaveloxolone restores metabolic and iron balance to reduce ferroptosis

  • Portillo-Carrasquer, Marta
  • Sanz Alcázar, Arabela
  • Sánchez López, Begoña
  • Delaspre, Fabien
  • Pazos-Gil, Maria
  • Oliveira-Jorge, Luiza
  • Castells i Roca, Laia
  • Tamarit Sumalla, Jordi
  • Ros Salvador, Joaquim
  • Cabiscol Català, Elisa
Friedreich ataxia (FA) is a rare, multisystemic neurodegenerative disorder caused by a deficiency of the mitochondrial protein frataxin. It is characterized by degeneration of the large sensory neurons in the dorsal root ganglia (DRG) and spinocerebellar tracts, leading to progressive neurodegeneration and muscle weakness. Frataxin deficiency induces iron dyshomeostasis, defective energy production, and oxidative stress, all regulated by NRF2. Omaveloxolone, an NRF2 activator, is currently the only approved therapy for FA; however, its effects on DRG neurons remain unknown. Here we used frataxin-deficient DRG neurons to better understand the drug's role in these sensory neurons. Omaveloxolone improved most of the analyzed parameters, including frataxin levels, cell survival, mitochondrial respiratory activity, iron homeostasis, oxidative stress, transferrin receptor 1 and glutathione peroxidase 4 levels, as well as the GSH/GSSG ratio. Moreover, lipid peroxidation, a key marker of ferroptosis that was increased in frataxin-deficient neurons, was almost completely rescued by omaveloxolone. Both total and nuclear NRF2 levels were decreased in frataxin-deficient neurons, and omaveloxolone treatment fully prevented this alteration. In addition, most of these results were validated in fibroblasts from FA patients. We also evaluated a combinatorial treatment using low doses of omaveloxolone together with honokiol, a SIRT3 activator with known neuroprotective properties. This combination enhanced cell survival and produced a synergistic effect increasing mitochondrial respiration in frataxin-deficient DRG neurons. In summary, these findings demonstrate the beneficial effects of omaveloxolone and further suggest that combination therapy with honokiol may provide an effective strategy for the treatment of FA, potentially mitigating adverse effects., This work was supported by: 1) Grant PID2020–118296RB-I00 funded by MICIU/AEI /10.13039/501100011033; 2) Grant PDC2021–120758-I00 funded by MICIU/AEI /10.13039/501100011033 and by the European Union NextGenerationEU/ PRTR; 3) Grant PID2023–148128OB-I00 funded by MICIU/AEI /10.13039/501100011033 and by FEDER, EU; 4) Project 2021-SGR 00323 funded by Generalitat de Catalunya. Marta Portillo-Carrasquer received a PhD fellowship from the Generalitat de Catalunya. Arabela Sanz-Alcázar received first a Ph.D. fellowship from the Generalitat de Catalunya and after, she held predoctoral fellowship “Ajuts al Personal Investigador en Formació " from IRBLleida/Diputació de Lleida. Begoña Sánchez López received a Ph.D. fellowship “Ayudas para la formación de Personal Investigador (FPI-2023)” from Ministerio de Ciencia, Innovación y Universidades. Maria Pazos received a PhD fellowship from the Universitat de Lleida. Luiza Olivera Jorge received a predoctoral fellowship “Ajuts de suport a departaments i unitats de recerca universitaris per a la contractació de personal investigador predoctoral en formació.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Pathological frataxin deficiency in mice causes tissue-specific alterations in iron homeostasis

  • Pazos Gil, Maria
  • Medina Carbonero, Marta
  • Sanz Alcázar, Arabela
  • Portillo-Carrasquer, Marta
  • Oliveira-Jorge, Luiza
  • Hernández, Gonzalo
  • Sánchez, Mayka
  • Delaspre, Fabien
  • Cabiscol Català, Elisa
  • Ros Salvador, Joaquim
  • Tamarit Sumalla, Jordi
Friedreich ataxia is caused by partial frataxin deficiency due to genetic mutations. It is well established that frataxin knockout affects iron homeostasis, but the alterations caused by pathological (partial) frataxin deficiency are poorly understood. In this study, we have analyzed iron homeostasis in a mouse model presenting pathological frataxin deficiency (FXNI151F). Our results reveal tissue-specific alterations of iron regulatory proteins (IRPs). In the heart, IRP2 accumulation is observed, likely triggered by iron-sulfur deficiency, while IRP1 is decreased in the cerebellum and liver. We also found elevated iron levels in mutant mice. Accumulation was particularly pronounced in the cerebellum, where increases were already evident at 10 weeks. Hepatic accumulation was not manifested until 21 weeks and was more pronounced in females. Overall, these findings indicate that frataxin deficiency disrupts iron homeostasis in a tissue-, age-, and sex-dependent manner, and provide novel insights into the mechanisms causing these perturbations., We thank Roser Pané for technical assistance, as well as the Proteomics and the Elemental Analysis Services from Universitat de Lleida, the Animal facilities from Universitat de Lleida, and the Lipidomics services from IRBLleida. We also thank Dr. Bruno Galy (Heidelberg) for providing samples from IRP2 KO mice. This study was supported by grant PID2020-118296RB-I00 from MCIN/AEI/10.13039/501100011033 (to J.R. and J.T.); grant PID2023-148128OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by FEDER, UE (to J.T. and E.C.); and grant PID2021-122436OB-I00 from MCIN/AEI/10.13039/501100011033/ERDF “A way to make Europe” (to M.S.), and by Association Française de l'Ataxie de Friedreich – AFAF (to F.D.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeting frataxin deficiency in DRG neurons and fibroblasts: omaveloxolone restores metabolic and iron balance to reduce ferroptosis

  • Portillo-Carrasquer, Marta
  • Sanz Alcázar, Arabela
  • Sánchez López, Begoña
  • Delaspre, Fabien
  • Pazos-Gil, Maria
  • Oliveira-Jorge, Luiza
  • Castells i Roca, Laia
  • Tamarit Sumalla, Jordi
  • Ros Salvador, Joaquim
  • Cabiscol Català, Elisa
Friedreich ataxia (FA) is a rare, multisystemic neurodegenerative disorder caused by a deficiency of the mitochondrial protein frataxin. It is characterized by degeneration of the large sensory neurons in the dorsal root ganglia (DRG) and spinocerebellar tracts, leading to progressive neurodegeneration and muscle weakness. Frataxin deficiency induces iron dyshomeostasis, defective energy production, and oxidative stress, all regulated by NRF2. Omaveloxolone, an NRF2 activator, is currently the only approved therapy for FA; however, its effects on DRG neurons remain unknown. Here we used frataxin-deficient DRG neurons to better understand the drug's role in these sensory neurons. Omaveloxolone improved most of the analyzed parameters, including frataxin levels, cell survival, mitochondrial respiratory activity, iron homeostasis, oxidative stress, transferrin receptor 1 and glutathione peroxidase 4 levels, as well as the GSH/GSSG ratio. Moreover, lipid peroxidation, a key marker of ferroptosis that was increased in frataxin-deficient neurons, was almost completely rescued by omaveloxolone. Both total and nuclear NRF2 levels were decreased in frataxin-deficient neurons, and omaveloxolone treatment fully prevented this alteration. In addition, most of these results were validated in fibroblasts from FA patients. We also evaluated a combinatorial treatment using low doses of omaveloxolone together with honokiol, a SIRT3 activator with known neuroprotective properties. This combination enhanced cell survival and produced a synergistic effect increasing mitochondrial respiration in frataxin-deficient DRG neurons. In summary, these findings demonstrate the beneficial effects of omaveloxolone and further suggest that combination therapy with honokiol may provide an effective strategy for the treatment of FA, potentially mitigating adverse effects., This work was supported by: 1) Grant PID2020–118296RB-I00 funded by MICIU/AEI /10.13039/501100011033; 2) Grant PDC2021–120758-I00 funded by MICIU/AEI /10.13039/501100011033 and by the European Union NextGenerationEU/ PRTR; 3) Grant PID2023–148128OB-I00 funded by MICIU/AEI /10.13039/501100011033 and by FEDER, EU; 4) Project 2021-SGR 00323 funded by Generalitat de Catalunya. Marta Portillo-Carrasquer received a PhD fellowship from the Generalitat de Catalunya. Arabela Sanz-Alcázar received first a Ph.D. fellowship from the Generalitat de Catalunya and after, she held predoctoral fellowship “Ajuts al Personal Investigador en Formació " from IRBLleida/Diputació de Lleida. Begoña Sánchez López received a Ph.D. fellowship “Ayudas para la formación de Personal Investigador (FPI-2023)” from Ministerio de Ciencia, Innovación y Universidades. Maria Pazos received a PhD fellowship from the Universitat de Lleida. Luiza Olivera Jorge received a predoctoral fellowship “Ajuts de suport a departaments i unitats de recerca universitaris per a la contractació de personal investigador predoctoral en formació.